Gamifant

(emapalumab-lzsg)
Gamifant 10 MG in 2 ML InjectionGamifant 50 MG in 10 ML Injection
View 5 more
NO BOXED WARNING

Dosage & administration

For intravenous infusion only:

drug label

Gamifant prescribing information

prior authorization

Gamifant prior authorization resources

Most recent Gamifant prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Learn More

Benefits investigation

Gamifant Cares Prescription & Enrollment Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

pharmacy

Gamifant preferred pharmacy

Pharmacy List

PubMed™ | Gamifant

Gamifant PubMed™ News

patient education

Gamifant patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Gamifant
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Gamifant
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources - Support Groups
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Gamifant Cares Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Primary Hemophagocytic Lymphohistiocytosis (HLH) Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Nurse Case Manager Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Gamifant FAQs

What is the drug-associated risk of adverse developmental outcomes in pregnant women using GAMIFANT?Limited data on the use of GAMIFANT in pregnant women do not identify a concern for specific adverse developmental outcomes. An animal reproduction study using a murine surrogate anti-mouse IFNγ antibody administered to pregnant mice throughout gestation did not show any fetal harm. However, the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
What is the estimated background risk of major birth defects and miscarriage in the general population?In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Is emapalumab-lzsg present in human milk?There is no information regarding the presence of emapalumab-lzsg in human milk. Published data suggest that only limited amounts of therapeutic antibodies are found in breast milk and they do not enter the neonatal and infant circulations in substantial amounts.
Is GAMIFANT safe and effective for use in pediatric patients?GAMIFANT has been established as safe and effective in pediatric patients with primary HLH that is reactivated or refractory to conventional therapies. Use of GAMIFANT is supported by a single-arm trial in 27 pediatric patients with reactivated or refractory primary HLH, including patients from newborn to 13 years of age.
Is there clinical data available on the use of GAMIFANT in geriatric patients?Clinical studies of GAMIFANT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
FAQ Data Source